Engineered human angiogenin mutations in the placental ribonuclease inhibitor complex for anticancer therapy: Insights from enhanced sampling simulations
- PMID: 27110669
- PMCID: PMC4972201
- DOI: 10.1002/pro.2941
Engineered human angiogenin mutations in the placental ribonuclease inhibitor complex for anticancer therapy: Insights from enhanced sampling simulations
Abstract
Targeted human cytolytic fusion proteins (hCFPs) represent a new generation of immunotoxins (ITs) for the specific targeting and elimination of malignant cell populations. Unlike conventional ITs, hCFPs comprise a human/humanized target cell-specific binding moiety (e.g., an antibody or a fragment thereof) fused to a human proapoptotic protein as the cytotoxic domain (effector domain). Therefore, hCFPs are humanized ITs expected to have low immunogenicity. This reduces side effects and allows long-term application. The human ribonuclease angiogenin (Ang) has been shown to be a promising effector domain candidate. However, the application of Ang-based hCFPs is largely hampered by the intracellular placental ribonuclease inhibitor (RNH1). It rapidly binds and inactivates Ang. Mutations altering Ang's affinity for RNH1 modulate the cytotoxicity of Ang-based hCFPs. Here we perform in total 2.7 µs replica-exchange molecular dynamics simulations to investigate some of these mutations-G85R/G86R (GGRRmut ), Q117G (QGmut ), and G85R/G86R/Q117G (GGRR/QGmut ). GGRRmut turns out to perturb greatly the overall Ang-RNH1 interactions, whereas QGmut optimizes them. Combining QGmut with GGRRmut compensates the effects of the latter. Our results explain the in vitro finding that, while Ang GGRRmut -based hCFPs resist RNH1 inhibition remarkably, Ang WT- and Ang QGmut -based ones are similarly sensitive to RNH1 inhibition, whereas Ang GGRR/QGmut -based ones are only slightly resistant. This work may help design novel Ang mutants with reduced affinity for RNH1 and improved cytotoxicity.
Keywords: angiogenin; apoptosis; cytolytic fusion protein; molecular dynamics; mutagenesis; replica exchange; ribonuclease inhibitor; targeted therapy.
© 2016 The Protein Society.
Figures







Similar articles
-
Designing the Sniper: Improving Targeted Human Cytolytic Fusion Proteins for Anti-Cancer Therapy via Molecular Simulation.Biomedicines. 2017 Feb 17;5(1):9. doi: 10.3390/biomedicines5010009. Biomedicines. 2017. PMID: 28536352 Free PMC article. Review.
-
Novel angiogenin mutants with increased cytotoxicity enhance the depletion of pro-inflammatory macrophages and leukemia cells ex vivo.Cancer Immunol Immunother. 2015 Dec;64(12):1575-86. doi: 10.1007/s00262-015-1763-8. Epub 2015 Oct 15. Cancer Immunol Immunother. 2015. PMID: 26472728 Free PMC article.
-
Angiogenin mutants as novel effector molecules for the generation of fusion proteins with increased cytotoxic potential.J Immunother. 2015 Apr;38(3):85-95. doi: 10.1097/CJI.0000000000000053. J Immunother. 2015. PMID: 25710248
-
Angiogenin single-chain immunofusions: influence of peptide linkers and spacers between fusion protein domains.Biochemistry. 1996 Jan 16;35(2):545-53. doi: 10.1021/bi951650w. Biochemistry. 1996. PMID: 8555226
-
Angiogenin (ANG)-Ribonuclease Inhibitor (RNH1) System in Protein Synthesis and Disease.Int J Mol Sci. 2021 Jan 28;22(3):1287. doi: 10.3390/ijms22031287. Int J Mol Sci. 2021. PMID: 33525475 Free PMC article. Review.
Cited by
-
Recombinant immunotoxins development for HER2-based targeted cancer therapies.Cancer Cell Int. 2021 Sep 6;21(1):470. doi: 10.1186/s12935-021-02182-6. Cancer Cell Int. 2021. PMID: 34488747 Free PMC article. Review.
-
Targeted human cytolytic fusion proteins at the cutting edge: harnessing the apoptosis-inducing properties of human enzymes for the selective elimination of tumor cells.Oncotarget. 2019 Jan 25;10(8):897-915. doi: 10.18632/oncotarget.26618. eCollection 2019 Jan 25. Oncotarget. 2019. PMID: 30783518 Free PMC article. Review.
-
Advances in epidermal growth factor receptor specific immunotherapy: lessons to be learned from armed antibodies.Oncotarget. 2020 Sep 22;11(38):3531-3557. doi: 10.18632/oncotarget.27730. eCollection 2020 Sep 22. Oncotarget. 2020. PMID: 33014289 Free PMC article. Review.
-
Designing the Sniper: Improving Targeted Human Cytolytic Fusion Proteins for Anti-Cancer Therapy via Molecular Simulation.Biomedicines. 2017 Feb 17;5(1):9. doi: 10.3390/biomedicines5010009. Biomedicines. 2017. PMID: 28536352 Free PMC article. Review.
-
CSPG4: A Target for Selective Delivery of Human Cytolytic Fusion Proteins and TRAIL.Biomedicines. 2017 Jun 28;5(3):37. doi: 10.3390/biomedicines5030037. Biomedicines. 2017. PMID: 28657611 Free PMC article. Review.
References
-
- Tsutsumi Y, Onda M, Nagata S, Lee B, Kreitman RJ, Pastan I (2000) Site‐specific chemical modification with polyethylene glycol of recombinant immunotoxin anti‐Tac(Fv)‐PE38 (LMB‐2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proc Natl Acad Sci USA 97:8548–8553. - PMC - PubMed
-
- Pai LH, FitzGerald DJ, Tepper M, Schacter B, Spitalny G, Pastan I (1990) Inhibition of antibody response to Pseudomonas exotoxin and an immunotoxin containing Pseudomonas exotoxin by 15‐deoxyspergualin in mice. Cancer Res 50:7750–7753. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous